country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-182358

Copy Link Print Information

TMLZ-G46

TMLZ-G46 is an orally active ZNF207 inhibitor with blood-brain barrier penetration ability, with a K_d value of 68 nM. TMLZ-G46 inhibits cancer cell proliferation, stemness, migration and invasion, induces G0/G1 cell cycle arrest and apoptosis, and suppresses colony formation. TMLZ-G46 can be used in glioma research.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr.: 3116767-83-7
Formel: C₃₇H₄₁N₃O₃
Molecular Weight:575.74

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

TMLZ-G46 Chemical Structure

CAS. Nr.: 3116767-83-7

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
- Parmacokinetics
- In Vivo
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

In Vitro

TMLZ-G46 (10 μM; 3 h) binds to ZNF207 in LN229 and U251MG glioma cells, and significantly increases the thermal stability of this protein^[1].
TMLZ-G46 (72 h) potently inhibits the proliferation of glioma cell lines with high ZNF207 expression (LN229, U251MG, HS683, T98G), with IC₅₀ values below 3 μM, while its activity decreases in cell lines with low ZNF207 expression (U87MG, U118MG, U138MG)^[1].
TMLZ-G46 (0.25-4 μM; 14 days) potently impairs the clonogenic capacity of LN229 and U251MG glioma cells, with significant inhibitory effects observable at concentrations as low as 0.25 μM^[1].
TMLZ-G46 (10 days) selectively inhibits the self-renewal of glioma stem-like cells in LN229 and U251MG cells, with an IC₅₀ value at the submicromolar level^[1].
TMLZ-G46 (0.5-4 μM; 24 h) dose-dependently inhibits the expression of SOX2 in LN229 and U251MG glioma cells, providing a basis for its inhibition of stem cell properties^[1].
TMLZ-G46 (0-8 μM; 24-48 h) inhibits the migration and invasion abilities of LN229 and U251MG glioma cells in a dose-dependent manner^[1].
TMLZ-G46 (1-5 μM; 24 h) induces G0/G1 cell cycle arrest and apoptosis in LN229 and U251MG glioma cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay^[1]

Cell Line:

LN229 glioma cell line, U251MG glioma cell line, HS683 glioma cell line, U87MG glioma cell line, U118MG glioma cell line, U138MG glioma cell line, T98G glioma cell line
Concentration:

/
Incubation Time:

72 h
Result:

Showed potent antiproliferative activity, with half-maximal inhibitory concentration (IC₅₀) values of 0.93 μM (LN229), 1.33 μM (U251MG), 2.07 μM (HS683), 2.05 μM (T98G), 4.82 μM (U87MG), 5.58 μM (U118MG), and 7.73 μM (U138MG).

Western Blot Analysis^[1]

Cell Line:

LN229 glioma cell line, U251MG glioma cell line
Concentration:

0.5, 1, 2, 4 μM
Incubation Time:

24 h
Result:

Downregulated SOX2 protein expression in a dose-dependent manner in both cell lines, with significant reduction observed at 2 μM and 4 μM.

Cell Cycle Analysis^[1]

Cell Line:

LN229 glioma cell line, U251MG glioma cell line
Concentration:

1, 5 μM
Incubation Time:

24 h
Result:

Induced G0/G1 cell cycle arrest.
Increased the G0/G1 fraction from 37.2% to 48.7% in LN229 cells at 5 μM.
Increased the G0/G1 fraction from 44.8% to 51.4% in U251MG cells at 5 μM.

Apoptosis Analysis^[1]

Cell Line:

LN229 glioma cell line, U251MG glioma cell line
Concentration:

1, 5 μM
Incubation Time:

24 h
Result:

Induced apoptosis.
Reached apoptotic rates of 52.3% in LN229 cells at 5 μM.
Reached apoptotic rates of 12.5% in U251MG cells at 5 μM.

Parmacokinetics

Species	Dose	Route	T_1/2	T_max	C_max	AUC_0-t	MRT	F	CL
Rat^[1]	5 (male) mg/kg	i.v.	0.31 h	0.083 h	2290.90 ng/mL	2546.66 ng·h/mL	0.44 h	/	76.67 mL/min
Rat^[1]	30 (male) mg/kg	p.o.	11.90 h	5.17 h	592.79 ng/mL	10405.67 ng·h/mL	19.52 h	68.1 %	/
Rat^[1]	5 (female) mg/kg	i.v.	0.28 h	0.083 h	1772.01 ng/mL	2006.24 ng·h/mL	0.41 h	/	130 mL/min
Rat^[1]	30 (female) mg/kg	p.o.	14.7 h	3.24 h	327.53 ng/mL	6340.88 ng·h/mL	22.24 h	52.7 %	/

In Vivo

TMLZ-G46 (60 mg/kg; p.o.; once daily; 28 days) achieves a tumor growth inhibition rate of 83.7% in mouse U251MG glioblastoma xenografts^[1].
TMLZ-G46 (30 mg/kg; i.g.; once daily; 60 days) reduces tumor burden of orthotopic U251MG glioblastoma xenografts in mice and significantly prolongs their survival, with efficacy comparable to that of Temozolomide (HY-17364)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

BALB/c nude (male, 6-8 weeks old, subcutaneous U251MG glioblastoma xenograft model)^[1]
Dosage:

60 mg/kg
Administration:

p.o.; once daily; 28 days
Result:

Achieved a tumor growth inhibition rate of 83.7% compared to vehicle control.
Reduced mean tumor volume and tumor weight.
Showed no significant changes in body weight, organ index (heart, liver, spleen, lung, kidney), serum AST/ALT activities, or histopathological alterations of major organs.
Reduced PCNA- and Ki67-positive tumor cells significantly.

Chemical Information

CAS. Nr. 3116767-83-7
Molecular Weight 575.74
Formel C₃₇H₄₁N₃O₃
SMILES

O=C(/C(C#N)=C1C2=CC=CC=C2OC3=CC=CC=C3\1)NCCC4CCN(CC4)CC5=CC=C(C=C5)OCC6CCCCC6
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Reinheit & Dokumentation

Handling Instructions (2659 KB)

Verweise

[1]. Gao M, et al. Discovery, Optimization, and Biological Evaluation of 2-Cyano-2-(9H-xanthen-9-ylidene)acetamide Derivatives as ZNF207 Inhibitors for Anti-Glioma Therapy. J Med Chem. Published online March 19, 2026. [Content Brief]

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen